转移性肾细胞癌中纳武利尤单抗-伊匹木单抗治疗失败后的二线靶向治疗
该研究回顾性分析了13家机构中Checkmate 214研究期间接受纳武利尤单抗-伊匹木单抗治疗后进展并接受后续TKI治疗的33例mRCC患者,中位随访22个月,TKI治疗中位PFS为8个月,12个月OS率为54%,42%出现≥3级毒性,一线双免疫治疗缓解持续时间≥6个月者二线PFS显著更长。
要点
- 纳武利尤单抗-伊匹木单抗失败后接受TKI的33例患者中,中位PFS为8个月,12个月OS率为54%。
- 一线双免疫治疗缓解持续时间≥6个月者二线TKI的PFS为8个月,短于6个月者为5个月(p=0.03)。
- 42%的患者出现至少一项≥3级毒性。
核心结论
- 这是首项报告一线纳武利尤单抗-伊匹木单抗治疗失败后TKI治疗结局的研究。
- 中位PFS提示TKI具有持续获益,支持开展探索最佳治疗顺序的临床试验。
研究设计与样本
- 回顾性收集13家机构中Checkmate 214研究期间接受纳武利尤单抗-伊匹木单抗治疗后接受后续TKI治疗的mRCC患者的病历资料。
- 共33例患者接受后续TKI治疗,从后续TKI开始计算的中位随访时间为22个月(19-NR)。
主要发现
- 30例患者可评估最佳缓解:部分缓解12例(36%),疾病稳定13例(39%),疾病进展5例(15%)。
- 从TKI开始计算的中位PFS为8个月[5-13]。
- 第一代TKI(舒尼替尼/帕唑帕尼)的中位PFS为8个月[5-16],第二代TKI(阿昔替尼/卡博替尼)的中位PFS为7个月(5-NA)。
- 一线双免疫治疗缓解持续时间≥6个月者二线PFS为8个月,短于6个月者为5个月(p=0.03)。
- 12个月OS率为54%;42%的患者出现至少一项≥3级毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of care for naïve patients with intermediate or poor risk prognosis (International mRCC Database Consortium). The efficacy of subsequent vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) after nivolumab-ipilimumab failure remains unclear. METHODS: Medical records of mRCC patients treated with nivolumab-ipilimumab, who received subsequent TKI, as part of Checkmate 214 study were reviewed in 13 institutions. Baseline characteristics, outcome data including progression-free survival (PFS), response, overall survival (OS) and toxicities were retrospectively collected. RESULTS: Overall 33 patients received subsequent TKI after nivolumab-ipilimumab failure. Median follow-up from start of subsequent TKI is 22 months (19-NR). Best response was assessed in 30 patients: 12 partial responses (36%), 13 stable diseases (39%) and five progressive diseases (15%). Median PFS from start of TKI was 8 months [5-13]. Median PFS with first-generation (sunitinib/pazopanib) and second-generation TKI (axitinib/cabozantinib) was 8 months [5-16] and 7 months (5-NA), respectively. PFS in second line was significantly longer in patients with a long first-line duration of response to the double immune checkpoint blockade (≥6 months) with 8 versus 5 months for short responder (<6 months) (p = 0.03). OS rate was 54% at 12 months. Toxicity was as expected: 42% developed at least one toxicity grade ≥3. CONCLUSION: This is the first report of outcomes with TKI, after first-line nivolumab-ipilimumab failure. Median PFS suggests a sustained benefit of TKI and supports trials investigating the optimal sequence.
引用
- Auvray M, Auclin E, Barthelemy P, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019. PMID: 30616146. doi:10.1016/j.ejca.2018.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。